Takeda Pharmaceutical (NYSE:TAK) Stock Gets Downgrade from Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

TAK has been the subject of several other reports. Weiss Ratings raised Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, November 3rd. Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy”.

Check Out Our Latest Stock Analysis on Takeda Pharmaceutical

Takeda Pharmaceutical Trading Up 0.0%

Shares of TAK stock opened at $21.43 on Friday. The firm has a 50 day moving average price of $19.40 and a two-hundred day moving average price of $17.78. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $68.68 billion, a PE ratio of 28.20 and a beta of -0.02. Takeda Pharmaceutical has a 12-month low of $13.91 and a 12-month high of $21.73.

Insider Buying and Selling at Takeda Pharmaceutical

In other news, insider Deidre Greenway sold 12,980 shares of Takeda Pharmaceutical stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total value of $235,067.80. Following the completion of the sale, the insider directly owned 40,049 shares in the company, valued at approximately $725,287.39. The trade was a 24.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lauren Duprey sold 34,535 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the sale, the insider owned 191,522 shares of the company’s stock, valued at approximately $3,550,817.88. This trade represents a 15.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 238,974 shares of company stock worth $4,549,461. 0.04% of the stock is currently owned by company insiders.

Institutional Trading of Takeda Pharmaceutical

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after buying an additional 370,800 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Takeda Pharmaceutical by 20.6% in the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares in the last quarter. Royal Bank of Canada increased its stake in shares of Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock valued at $11,386,000 after purchasing an additional 60,725 shares during the last quarter. Bleakley Financial Group LLC increased its stake in shares of Takeda Pharmaceutical by 2.8% in the 3rd quarter. Bleakley Financial Group LLC now owns 444,988 shares of the company’s stock valued at $8,094,000 after purchasing an additional 12,032 shares during the last quarter. Finally, Ethic Inc. increased its stake in shares of Takeda Pharmaceutical by 19.5% in the 3rd quarter. Ethic Inc. now owns 436,514 shares of the company’s stock valued at $7,940,000 after purchasing an additional 71,261 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

(Get Free Report)

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Recommended Stories

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.